Search Page

1

Cite

Share

Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients.

Fujii S, Huang S, Fong TC, Ando D, Burrows F, Jolly DJ, Nemunaitis J, Hoon DS. Fujii S, et al. Among authors: nemunaitis j. Cancer Gene Ther. 2000 Sep;7(9):1220-30. doi: 10.1038/sj.cgt.7700224. Cancer Gene Ther. 2000. PMID: 11023194 Clinical Trial.

Cite

Share

2

Cite

Share

Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.

Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A. Nemunaitis J, et al. Clin Cancer Res. 1998 May;4(5):1101-9. Clin Cancer Res. 1998. PMID: 9607566 Clinical Trial.

Cite

Share

3

Cite

Share

Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma.

Nemunaitis J, Bohart C, Fong T, Meyer W, Edelman G, Paulson RS, Orr D, Jain V, O'Brien J, Kuhn J, Kowal KJ, Burkeholder S, Bruce J, Ognoskie N, Wynne D, Martineau D, Ando D. Nemunaitis J, et al. Cancer Gene Ther. 1998 Sep-Oct;5(5):292-300. Cancer Gene Ther. 1998. PMID: 9824048 Clinical Trial.

Cite

Share

4

Cite

Share

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.

Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB Jr, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK. Swisher SG, et al. Among authors: nemunaitis j. J Natl Cancer Inst. 1999 May 5;91(9):763-71. doi: 10.1093/jnci/91.9.763. J Natl Cancer Inst. 1999. PMID: 10328106 Clinical Trial.

Cite

Share

5

Cite

Share

Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma.

Nemunaitis J, Fong T, Burrows F, Bruce J, Peters G, Ognoskie N, Meyer W, Wynne D, Kerr R, Pippen J, Oldham F, Ando D. Nemunaitis J, et al. Hum Gene Ther. 1999 May 20;10(8):1289-98. doi: 10.1089/10430349950017978. Hum Gene Ther. 1999. PMID: 10365660 Clinical Trial.

Cite

Share

6

Cite

Share

Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.

Nemunaitis J, Fong T, Robbins JM, Edelman G, Edwards W, Paulson RS, Bruce J, Ognoskie N, Wynne D, Pike M, Kowal K, Merritt J, Ando D. Nemunaitis J, et al. Cancer Gene Ther. 1999 Jul-Aug;6(4):322-30. doi: 10.1038/sj.cgt.7700019. Cancer Gene Ther. 1999. PMID: 10419050 Clinical Trial.

Cite

Share

7

Cite

Share

Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.

Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J. Nemunaitis J, et al. J Clin Oncol. 2000 Feb;18(3):609-22. doi: 10.1200/JCO.2000.18.3.609. J Clin Oncol. 2000. PMID: 10653876 Clinical Trial.

Cite

Share

8

Cite

Share

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH. Khuri FR, et al. Among authors: nemunaitis j. Nat Med. 2000 Aug;6(8):879-85. doi: 10.1038/78638. Nat Med. 2000. PMID: 10932224 Clinical Trial.

Cite

Share

9

Cite

Share

A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).

Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM. Lamont JP, et al. Among authors: nemunaitis j. Ann Surg Oncol. 2000 Sep;7(8):588-92. doi: 10.1007/BF02725338. Ann Surg Oncol. 2000. PMID: 11005557 Clinical Trial.

Cite

Share

10

Cite

Share

Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors.

Nemunaitis J, Eager R, Twaddell T, Corey A, Sekar K, Tkaczuk K, Thompson J, Hoff PM, Pazdur R. Nemunaitis J, et al. J Clin Oncol. 2000 Oct 1;18(19):3423-34. doi: 10.1200/JCO.2000.18.19.3423. J Clin Oncol. 2000. PMID: 11013283 Clinical Trial.

Cite

Share